Sudan Loganathan
Stock Analyst at Stephens & Co.
(3.68)
# 693
Out of 5,090 analysts
42
Total ratings
54.29%
Success rate
8.24%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PYXS Pyxis Oncology | Maintains: Overweight | $5 → $8 | $4.22 | +89.57% | 2 | Nov 24, 2025 | |
| IMNM Immunome | Maintains: Overweight | $25 → $33 | $19.76 | +67.00% | 3 | Nov 17, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $14 → $15 | $12.79 | +17.28% | 3 | Nov 10, 2025 | |
| DCTH Delcath Systems | Maintains: Overweight | $25 → $18 | $9.78 | +84.05% | 4 | Nov 5, 2025 | |
| CADL Candel Therapeutics | Initiates: Overweight | $15 | $5.33 | +181.43% | 1 | Oct 28, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $35 | $29.91 | +17.02% | 1 | Oct 28, 2025 | |
| CCCC C4 Therapeutics | Reiterates: Overweight | $6 | $2.67 | +124.72% | 3 | Sep 22, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $45 | $35.87 | +25.45% | 3 | Sep 9, 2025 | |
| NRIX Nurix Therapeutics | Reiterates: Overweight | $30 | $18.09 | +65.84% | 4 | Jul 10, 2025 | |
| EXEL Exelixis | Upgrades: Overweight | $29 → $60 | $44.36 | +35.26% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $33 | $23.53 | +40.25% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $8 | $3.29 | +143.16% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $15 | $7.07 | +112.16% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $60 | $66.62 | -9.94% | 2 | Jan 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.43 | +249.65% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $9.72 | +928.81% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.07 | +866.18% | 1 | May 14, 2024 |
Pyxis Oncology
Nov 24, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $4.22
Upside: +89.57%
Immunome
Nov 17, 2025
Maintains: Overweight
Price Target: $25 → $33
Current: $19.76
Upside: +67.00%
Arvinas
Nov 10, 2025
Maintains: Overweight
Price Target: $14 → $15
Current: $12.79
Upside: +17.28%
Delcath Systems
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $18
Current: $9.78
Upside: +84.05%
Candel Therapeutics
Oct 28, 2025
Initiates: Overweight
Price Target: $15
Current: $5.33
Upside: +181.43%
Centessa Pharmaceuticals
Oct 28, 2025
Initiates: Overweight
Price Target: $35
Current: $29.91
Upside: +17.02%
C4 Therapeutics
Sep 22, 2025
Reiterates: Overweight
Price Target: $6
Current: $2.67
Upside: +124.72%
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: $45
Current: $35.87
Upside: +25.45%
Nurix Therapeutics
Jul 10, 2025
Reiterates: Overweight
Price Target: $30
Current: $18.09
Upside: +65.84%
Exelixis
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $44.36
Upside: +35.26%
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $23.53
Upside: +40.25%
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $3.29
Upside: +143.16%
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $7.07
Upside: +112.16%
Jan 21, 2025
Reiterates: Overweight
Price Target: $60
Current: $66.62
Upside: -9.94%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.43
Upside: +249.65%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $9.72
Upside: +928.81%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $2.07
Upside: +866.18%